Liquid biopsy is a test that examines deoxyribonucleic acid (DNA) and other molecules in a patient’s blood to detect cancer. Liquid biopsy plays a key role in early cancer detection by providing a non-invasive method for detecting the presence of cancer cells in the body.
This test can detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in patients’ blood, indicating the presence of cancer before symptoms appear or before a tumor can be seen on imaging tests.
This allows for earlier cancer detection, leading to earlier treatment and potentially better outcomes for patients. Additionally, liquid biopsy can also be used to monitor the progression of cancer and assess the effectiveness of treatment, helping make treatment decisions and decision making to continue or change therapy.
The healthcare industry has quickly embraced liquid biopsy technology for its accuracy, speed, and convenience. It is used in many hospitals and clinics worldwide and is becoming an integral part of the healthcare industry. With its ability to detect cancer in its early stages and with minimal discomfort to the patient, it is revolutionizing the way healthcare professionals diagnose and treat cancer.